Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)

Creative Commons License

Pagidipati N. J., Navar A. M., Pieper K. S., Green J. B., Bethel M. A., Armstrong P. W., ...More

CIRCULATION, vol.136, no.13, pp.1193-1205, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 136 Issue: 13
  • Publication Date: 2017
  • Doi Number: 10.1161/circulationaha.117.027252
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1193-1205
  • Hacettepe University Affiliated: Yes


BACKGROUND: Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which secondary prevention treatment goals are achieved in international clinical practice is unknown.